PMID- 30084185
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20190819
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 21
IP  - 1
DP  - 2019 Jan
TI  - Endogenous glucagon-like peptide-1 system response is impaired during 
      ST-elevation myocardial infarction in type 2 diabetes patients.
PG  - 194-198
LID - 10.1111/dom.13490 [doi]
AB  - We previously demonstrated increased glucagon-like peptide-1 (GLP-1) secretion 
      during acute ST elevation myocardial infarction (STEMI) in non-diabetic (ND) 
      patients. Whether the endogenous GLP-1 system response is different in patients 
      with type 2 diabetes (T2D) during STEMI is unknown. Patients with STEMI (20 ND, 
      13 T2D) and 3 control groups (non-STEMI [14 ND, 13 T2D], stable angina pectoris 
      [SAP] [8 ND, 10 T2D] patients and healthy subjects) (n = 25) were studied. Plasma 
      levels of total and active GLP-1 and soluble dipeptidyl peptidase-4 (sDPP4) were 
      estimated by enzyme-linked immunosorbent assay on admission and at 24 and 48 
      hours after percutaneous coronary intervention in all patients. Sharply elevated 
      levels of total and active GLP-1 were found in ND STEMI patients at 24 h (P < 
      0.05 and P < 0.005, respectively), but not in T2D STEMI patients. All patients 
      demonstrated decreased sDPP4 levels compared with healthy controls (P < 0.0005) 
      accompanied by increased active/total GLP-1 ratio regardless of their ischemic 
      state. These data demonstrate that T2D patients fail to further upregulate their 
      endogenous GLP-1 system during STEMI. This may underlie their worse 
      cardiovascular outcome.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Elbaz-Greener, Gabby
AU  - Elbaz-Greener G
AD  - Intensive Coronary Care Unit, Assaf Harofeh Medical Center Affiliated to Sackler 
      Medical School Tel Aviv University, Zerifin, Israel.
FAU - Bloch, Olga
AU  - Bloch O
AD  - Diabetes Research Laboratory, Assaf Harofeh Medical Center Affiliated to Sackler 
      Medical School, Tel Aviv University, Zerifin, Israel.
FAU - Kumets, Ilya
AU  - Kumets I
AD  - Department "C" of Internal Medicine, Assaf Harofeh Medical Center Affiliated to 
      Sackler Medical School, Tel Aviv University, Zerifin, Israel.
FAU - Blatt, Alex
AU  - Blatt A
AD  - Intensive Coronary Care Unit, Assaf Harofeh Medical Center Affiliated to Sackler 
      Medical School Tel Aviv University, Zerifin, Israel.
FAU - Rapoport, Micha J
AU  - Rapoport MJ
AUID- ORCID: 0000-0002-6925-2041
AD  - Diabetes Research Laboratory, Assaf Harofeh Medical Center Affiliated to Sackler 
      Medical School, Tel Aviv University, Zerifin, Israel.
AD  - Department "C" of Internal Medicine, Assaf Harofeh Medical Center Affiliated to 
      Sackler Medical School, Tel Aviv University, Zerifin, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180905
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Diabetes Mellitus, Type 2/*complications/epidemiology
MH  - Dipeptidyl Peptidase 4/metabolism
MH  - Female
MH  - Glucagon-Like Peptide 1/blood/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - ST Elevation Myocardial Infarction/*complications/epidemiology/*metabolism
OTO - NOTNLM
OT  - ST-elevation myocardial infarction
OT  - endogenous GLP-1 system
OT  - soluble DPP4
OT  - type 2 diabetes
EDAT- 2018/08/08 06:00
MHDA- 2019/08/20 06:00
CRDT- 2018/08/08 06:00
PHST- 2018/05/13 00:00 [received]
PHST- 2018/07/18 00:00 [revised]
PHST- 2018/08/01 00:00 [accepted]
PHST- 2018/08/08 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
PHST- 2018/08/08 06:00 [entrez]
AID - 10.1111/dom.13490 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2019 Jan;21(1):194-198. doi: 10.1111/dom.13490. Epub 2018 
      Sep 5.